Human VEGFR2/KDR/Flk‑1 Biotinylated Antibody Best Seller

Detection of Human VEGFR2/KDR/Flk-1 by ELISA

Humoral response in pre-clinical models. Specific IgG antibodies were detected by ELISA using GST-hVEGF as coating antigen (a, b, d and f). The ability of animal sera antibodies to block VEGF/VEGFR2 interaction was determined using a competitive ELISA, where a soluble VEGFR2 competes with diluted serum in plates coated with GST-hVEGF (c, e and g). CIGB-247 combinations using VSSP or aluminum phosphate as adjuvants were administered weekly (eight vaccinations) or bi-weekly (four vaccinations) respectively. Horizontal bars represent the mean values of antibody titer or blocking activity, which are shown for each group. p-Values were calculated according to unpaired t-test. Reference dose (A + V): 400 μg of antigen + 200 μg of VSSP; (¼Ag + ½ V): 100 μg of antigen + 100 μg of VSSP; (¼Ag + V): 100 μg of antigen + 200 μg of VSSP; (Ag + Al): 400 μg of antigen + aluminum phosphate Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28747172), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human VEGFR2/KDR/Flk-1 by ELISA

Humoral response in pre-clinical models. Specific IgG antibodies were detected by ELISA using GST-hVEGF as coating antigen (a, b, d and f). The ability of animal sera antibodies to block VEGF/VEGFR2 interaction was determined using a competitive ELISA, where a soluble VEGFR2 competes with diluted serum in plates coated with GST-hVEGF (c, e and g). CIGB-247 combinations using VSSP or aluminum phosphate as adjuvants were administered weekly (eight vaccinations) or bi-weekly (four vaccinations) respectively. Horizontal bars represent the mean values of antibody titer or blocking activity, which are shown for each group. p-Values were calculated according to unpaired t-test. Reference dose (A + V): 400 μg of antigen + 200 μg of VSSP; (¼Ag + ½ V): 100 μg of antigen + 100 μg of VSSP; (¼Ag + V): 100 μg of antigen + 200 μg of VSSP; (Ag + Al): 400 μg of antigen + aluminum phosphate Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28747172), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human VEGFR2/KDR/Flk-1 by ELISA

Humoral response in pre-clinical models. Specific IgG antibodies were detected by ELISA using GST-hVEGF as coating antigen (a, b, d and f). The ability of animal sera antibodies to block VEGF/VEGFR2 interaction was determined using a competitive ELISA, where a soluble VEGFR2 competes with diluted serum in plates coated with GST-hVEGF (c, e and g). CIGB-247 combinations using VSSP or aluminum phosphate as adjuvants were administered weekly (eight vaccinations) or bi-weekly (four vaccinations) respectively. Horizontal bars represent the mean values of antibody titer or blocking activity, which are shown for each group. p-Values were calculated according to unpaired t-test. Reference dose (A + V): 400 μg of antigen + 200 μg of VSSP; (¼Ag + ½ V): 100 μg of antigen + 100 μg of VSSP; (¼Ag + V): 100 μg of antigen + 200 μg of VSSP; (Ag + Al): 400 μg of antigen + aluminum phosphate Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28747172), licensed under a CC-BY license. Not internally tested by R&D Systems.